about
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of integrin-linked kinase (ILK).Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristineIrinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicitiesValidating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhIrinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.The liposomal formulation of doxorubicin.Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells.Pharmacodynamic behavior of liposomal antisense oligonucleotides targeting Her-2/neu and vascular endothelial growth factor in an ascitic MDA435/LCC6 human breast cancer model.Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.Retraction. A novel combination of Chinese medicines to treat advanced cancers and lymphomas tested in rats.Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors.A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.Preparation, Characterization, and Biological Analysis of Liposomal Formulations of VincristineA novel combination of Chinese medicines to treat advanced cancers and lymphomas in ratsA Low Carbohydrate, High Protein Diet Slows Tumor Growth and Prevents Cancer InitiationModulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructsTemporal targeting in cancer: combined chemotherapy and antiangiogenic therapyLipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapyThe role of the transition metal copper and the ionophore A23187 in the development of Irinophore C™
P50
Q33209295-7897FC2F-02F8-4B74-B3C6-7B77D67A9A57Q33315215-B64FDBBC-DA30-40F8-B885-97948411E19DQ33866374-4943AEE9-8CF0-47F5-B676-C2C68EABED54Q34484362-73693647-AEDE-47DE-AA05-938CCE0A4CB3Q35001420-84B78EC1-9FA0-4D2E-A596-48DE458DE8C9Q35511589-82E87A09-4936-4FC2-BF23-B8543738A417Q36049002-31D392E2-784C-4ED8-B64C-769C8F0FE63BQ38287723-D3D24661-F26E-45E2-BCE9-D9E68B295962Q38345955-C30FEEC0-1AAD-4A25-A74C-4A812768BC15Q38822576-B20196B8-16C3-4381-BA1B-B994A865BDFFQ39457556-386CA3D2-CB42-4388-99DC-36907B33B4A3Q39574525-1E20907C-CC04-47C5-9293-9DA378516D67Q39861934-3AA088B8-90A6-4513-A295-A8F05C174EA7Q40505774-266705A5-148D-4069-8194-065EB7194E40Q46748236-CFDCFA38-A61A-473E-AA0F-C1D4FFD0D75EQ46974940-881DFE9E-913C-445C-92D2-A7FC72663851Q56456249-1704D8F8-9B01-4F14-8BE8-6E0A50808B80Q56576971-11E5BDC9-7981-4C16-8688-05D8FAA82292Q60313824-29360F85-E900-470D-8525-87C61AF76732Q79880199-600A1171-6ED9-448E-BF14-402759BB1B31Q80836326-84056B6A-3FD7-463C-8F1C-1B74F0394B55Q82473384-AEFFE929-CD69-4935-86C7-ACA3EFC67175Q83013066-3F011B39-E2AF-4CAA-B3DA-D998177A4AA1
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Dawn Waterhouse
@ast
Dawn Waterhouse
@en
Dawn Waterhouse
@es
Dawn Waterhouse
@nl
Dawn Waterhouse
@sl
type
label
Dawn Waterhouse
@ast
Dawn Waterhouse
@en
Dawn Waterhouse
@es
Dawn Waterhouse
@nl
Dawn Waterhouse
@sl
prefLabel
Dawn Waterhouse
@ast
Dawn Waterhouse
@en
Dawn Waterhouse
@es
Dawn Waterhouse
@nl
Dawn Waterhouse
@sl
P106
P21
P31
P496
0000-0001-9810-450X